Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001562180-25-002392
Filing Date
2025-03-14
Accepted
2025-03-14 08:02:56
Documents
2
Period of Report
2025-03-12

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT primarydocument.html 4  
1 PRIMARY DOCUMENT primarydocument.xml 4 10380
2 FEB POA kvpoafeb.txt EX-24 3961
  Complete submission text file 0001562180-25-002392.txt   15904
Mailing Address 175 INNOVATION BOULEVARD WILMINGTON DE 19805
Business Address 175 INNOVATION BOULEVARD WILMINGTON DE 19805 (302) 467-1280
Prelude Therapeutics Inc (Issuer) CIK: 0001678660 (see all company filings)

EIN.: 811384762 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O PRELUDE THERAPEUTICS INCORPORATED 200 POWDER MILL ROAD WILMINGTON DE 19803
Business Address
Vaddi Krishna (Reporting) CIK: 0001824633 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39527 | Film No.: 25737700